 |
13 Diseases |  |
3 Trials |
|
3 Trials |  |
119 News |  |
| «123» |
- GSK3901961 / GSK
[VIRTUAL] CD8Α-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2502;
P1
Exploratory endpoints include laboratory parameters, overall survival, progression-free survival, disease control rate, time to response, and anti-GSK3901961 titers. The study is currently open and recruiting.
- GSK3901961 / GSK
[VIRTUAL] CD8Α-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2501;
P1
Exploratory endpoints include laboratory parameters, overall survival, progression-free survival, disease control rate, time to response, and anti-GSK3901961 titers. The study is currently open and recruiting.
- GSK3901961 / GSK
[VIRTUAL] CD8Α-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2500;
P1
Exploratory endpoints include laboratory parameters, overall survival, progression-free survival, disease control rate, time to response, and anti-GSK3901961 titers. The study is currently open and recruiting.
- || letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion, Trial completion date, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jan 27, 2021
P1, N=10, Completed, Sponsor: GlaxoSmithKline
The study is currently open and recruiting. Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Aug 2020
- GSK3901961 / GSK
[VIRTUAL] CD8α-Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1 (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_644;
P1
The study is currently open and recruiting. Figure 1: Study design
- ||||||| letetresgene autoleucel (GSK3377794) / GSK
Clinical: NEWS from #SITC2020 @sitcancer - T-cell receptor therapy letetresgene autoleucel (@Adaptimmune @GSK) safe and clinically active in patients with advanced synovial sarcoma https://t.co/8EcBOUBJHC Data presented by @sandrapdangelo Sandra P. D'Angelo, MD @sloan_kettering (Twitter) - Nov 16, 2020
- letetresgene autoleucel (GSK3377794) / GSK
[VIRTUAL] FINAL ANALYSIS OF THE PHASE 1 TRIAL OF NY-ESO-1-SPECIFIC T-CELL RECEPTOR (TCR) T-CELL THERAPY (LETETRESGENE AUTOLEUCEL; GSK3377794) IN PATIENTS (PTS) WITH ADVANCED SYNOVIAL SARCOMA (SS) () - Nov 2, 2020 - Abstract #CTOS2020CTOS_18;
- letetresgene autoleucel (GSK3377794) / GSK, NY-ESO-1 TCR / National Cancer Institute, Gilead
[VIRTUAL] MODELING THE EFFICACY OF NY-ESO-1 TCR T CELLS (LETETRESGENE AUTOLEUCEL; GSK3377794) IN PATIENTS WITH SYNOVIAL SARCOMA: CORRELATIONS OF RESPONSE WITH TRANSDUCED CELL KINETICS AND BIOMARKERS () - Nov 2, 2020 - Abstract #CTOS2020CTOS_14;
- TCR transduced autologous T cells / Adaptimmune
[VIRTUAL] Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS) () - Oct 14, 2020 - Abstract #SITC2020SITC_1332;
P1
No patients tested positive for replication-competent lentivirus. Conclusions In patients with advanced SS who need effective treatment, lete-cel had a manageable safety profile; responses occurred in all cohorts, but patients with high NY-ESO-1 expression and more intensive lymphodepletion regimen received greatest benefit.
- NY-ESO-1 TCR / National Cancer Institute, Gilead
[VIRTUAL] Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers () - Oct 14, 2020 - Abstract #SITC2020SITC_1331;
P1
IFNγ, IL-6, and IL-2RA levels appear to be promising pharmacodynamic markers. Optimizing dose and LDR may offer opportunities to maximize antitumor efficacy.
- decitabine / Generic mfg.
[VIRTUAL] Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo () - Oct 14, 2020 - Abstract #SITC2020SITC_1138;
P1b/2a
Conclusions GSK is currently enrolling a Phase Ib/IIa, multi-arm, open-label pilot study (NCT03709706) of lete-cel as a monotherapy or in combination with pembrolizumab in HLA-A*02–positive patients with NSCLC whose tumors express NY-ESO-1/LAGE-1a. This work may support rationale for the use of DAC in combination with lete-cel to improve adoptive T-cell therapy by increasing levels of target antigens and antitumor effect in NSCLC.
- TCR transduced autologous T cells / Adaptimmune
[VIRTUAL] Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS) () - Oct 14, 2020 - Abstract #SITC2020SITC_597;
P1
No patients tested positive for replication-competent lentivirus. Conclusions In patients with advanced SS who need effective treatment, lete-cel had a manageable safety profile; responses occurred in all cohorts, but patients with high NY-ESO-1 expression and more intensive lymphodepletion regimen received greatest benefit.
- NY-ESO-1 TCR / National Cancer Institute, Gilead
[VIRTUAL] Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers () - Oct 14, 2020 - Abstract #SITC2020SITC_596;
P1
IFNγ, IL-6, and IL-2RA levels appear to be promising pharmacodynamic markers. Optimizing dose and LDR may offer opportunities to maximize antitumor efficacy.
- decitabine / Generic mfg.
[VIRTUAL] Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo () - Oct 14, 2020 - Abstract #SITC2020SITC_403;
P1b/2a
Conclusions GSK is currently enrolling a Phase Ib/IIa, multi-arm, open-label pilot study (NCT03709706) of lete-cel as a monotherapy or in combination with pembrolizumab in HLA-A*02–positive patients with NSCLC whose tumors express NY-ESO-1/LAGE-1a. This work may support rationale for the use of DAC in combination with lete-cel to improve adoptive T-cell therapy by increasing levels of target antigens and antitumor effect in NSCLC.
- || letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion date, Trial primary completion date, Combination therapy: IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov) - Aug 12, 2020
P2, N=65, Recruiting, Sponsor: GlaxoSmithKline
This work may support rationale for the use of DAC in combination with lete-cel to improve adoptive T-cell therapy by increasing levels of target antigens and antitumor effect in NSCLC. Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Jan 2022 --> Nov 2022
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion date, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 8, 2020
P1, N=10, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Jan 2022 --> Nov 2022 Trial completion date: Aug 2020 --> Dec 2021
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion date, Trial primary completion date, Metastases: ADP-0011-007: Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma (clinicaltrials.gov) - Aug 8, 2020
P2, N=20, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Aug 2020 --> Dec 2021 Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: Jun 2021 --> Oct 2021
- || Keytruda (pembrolizumab) / Merck (MSD), letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion date, Trial primary completion date, Metastases: Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab (clinicaltrials.gov) - Jul 17, 2020
P1b/2a, N=54, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: Jun 2021 --> Oct 2021 Trial completion date: Jul 2021 --> May 2025 | Trial primary completion date: Jul 2021 --> May 2025
- | cyclophosphamide intravenous / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. (Pubmed Central) - Jul 16, 2020
P1
From these data, we conclude that a lymphodepletion regimen containing high doses of fludarabine and cyclophosphamide is necessary for SPEAR T-cell persistence and efficacy. Furthermore, these data demonstrate that non-T-cell inflamed tumors, which are resistant to PD-1/PD-L1 inhibitors, can be treated with adoptive T-cell based immunotherapy.
- Keytruda (pembrolizumab) / Merck (MSD), cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] OPEN-LABEL PILOT STUDY OF GENETICALLY ENGINEERED NY-ESO-1–SPECIFIC T CELLS (GSK3377794) ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA () - May 16, 2020 - Abstract #EHA2020EHA_2454;
P2
Patients in both arms will provide cells via leukapheresis to manufacture autologous NY-ESO-1–specific T cells, undergo lymphodepletion (fludarabine + cyclophosphamide), and then receive GSK3377794 infusion (1−8x109 transduced T cells)...Results - Conclusion As of January 2020, 3 patients have been treated. Funding: GlaxoSmithKline (208470).
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion date, PD(L)-1 Biomarker: KEYNOTE-487: Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma (clinicaltrials.gov) - May 7, 2020
P2, N=20, Recruiting, Sponsor: GlaxoSmithKline
Funding: GlaxoSmithKline (208470). Trial completion date: Apr 2021 --> Jan 2023
- GSK3377794 / GSK
[VIRTUAL] Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO). (Poster Board 459) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2591;
P2
A similar presentation (P453) was presented at the SITC Annual Meeting, National Harbor, MD, USA, Nov 6–10, 2019. Funding: GlaxoSmithKline (208467) Research Funding: GlaxoSmithKline
- Keytruda (pembrolizumab) / Merck (MSD), cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma. (Poster Board 455) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2261;
P2
Patients in both arms will provide cells via leukapheresis to manufacture autologous NY-ESO-1–specific T cells, undergo lymphodepletion (fludarabine + cyclophosphamide), and then receive GSK3377794 infusion (1−8x109 transduced T cells)...As of January 2020, 3 patients have been treated. Funding: GlaxoSmithKline (208470) Research Funding: GlaxoSmithKline
- || letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion, Trial completion date, Trial primary completion date: ADP 04511: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1? (clinicaltrials.gov) - Feb 28, 2020
P1, N=45, Completed, Sponsor: GlaxoSmithKline
Funding: GlaxoSmithKline (208470) Research Funding: GlaxoSmithKline Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Jun 2019
- GSK3377794 / GSK
IO + GSK3377794 (STARLIGHT BALLROOM) - Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_295;
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion date, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 10, 2020
P1, N=10, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Jun 2019 Trial completion date: Dec 2021 --> Aug 2020
- Keytruda (pembrolizumab) / Merck (MSD), cyclophosphamide intravenous / Generic mfg.
Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma (World Center Marriott - Palms & Cypress Foyers) - Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1217;
P1, P2
A similar presentation will be presented at the ASH Annual Meeting, Orlando, FL, USA, Dec 7-10, 2019. This study (NCT03168438) is funded by GSK.
- ||| letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment open, Combination therapy: IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov) - Jan 13, 2020
P2, N=65, Recruiting, Sponsor: GlaxoSmithKline
This study (NCT03168438) is funded by GSK. Not yet recruiting --> Recruiting
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion date, Trial primary completion date, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 26, 2019
P1, N=10, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial completion date: Sep 2020 --> Dec 2021 | Trial primary completion date: Feb 2020 --> Jun 2020
- Keytruda (pembrolizumab) / Merck (MSD)
Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_4329;
P1, P2
Acknowledgment: Medical writing support by O Conn PhD of Fishawack Indicia Ltd, funded by GSK. This study (NCT03168438) is funded by GSK.
- GSK3377794 / GSK
CLINICAL STUDY TO EVALUATE SAFETY AND ACTIVITY OF AUTOLOGOUS T CELLS WITH ENHANCED NY-ESO-1-SPECIFIC T-CELL RECEPTOR (GSK3377794) IN HLA-A*02+ PREVIOUSLY-TREATED AND PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED METASTATIC OR UNRESECTABLE SYNOVIAL SARCOMA AS PART OF A MASTER PROTOCOL DESIGN () - Oct 24, 2019 - Abstract #CTOS2019CTOS_37;
- GSK3377794 / GSK
PHASE 1 TRIAL OF NY-ESO-1-SPECIFIC ADOPTIVE T-CELL THERAPY WITH GSK3377794 IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA () - Oct 24, 2019 - Abstract #CTOS2019CTOS_35;
- GSK3377794 / GSK
NY-ESO-1 TCR T (GSK3377794)– CASE STUDIES – SARCOMA AND MRCLS – CORRELATES OF PREDICTABLE RESPONSE CHARACTERISTICS () - Oct 24, 2019 - Abstract #CTOS2019CTOS_34;
- GSK3377794 / GSK
GSK3377794 – TWO CASE STUDIES – ACUTE INFLAMMATORY DEMYELINATING NEUROPATHY () - Oct 24, 2019 - Abstract #CTOS2019CTOS_6;
- GSK3377794 / GSK
CLINICAL STUDY TO EVALUATE SAFETY AND ACTIVITY OF AUTOLOGOUS T CELLS WITH ENHANCED NY-ESO-1-SPECIFIC T-CELL RECEPTOR (GSK3377794) IN HLA-A*02+ PREVIOUSLY-TREATED AND PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED METASTATIC OR UNRESECTABLE SYNOVIAL SARCOMA AS PART OF A MASTER PROTOCOL DESIGN () - Oct 24, 2019 - Abstract #CTOS2019CTOS_5;
- GSK3377794 / GSK
PHASE 1 TRIAL OF NY-ESO-1-SPECIFIC ADOPTIVE T-CELL THERAPY WITH GSK3377794 IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA () - Oct 24, 2019 - Abstract #CTOS2019CTOS_2;
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date, Combination therapy: IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov) - Oct 21, 2019
P2, N=65, Not yet recruiting, Sponsor: GlaxoSmithKline
This study (NCT03168438) is funded by GSK. Trial primary completion date: Apr 2021 --> Jan 2022
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date, Combination therapy: IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov) - Oct 15, 2019
P2, N=65, Not yet recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Apr 2021 --> Jan 2022 Trial primary completion date: Jul 2021 --> Apr 2021
- GSK3377794 / GSK
Autologous T cells with NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-A*02+ previously-treated and -untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_814;
P2
Based on the encouraging clinical activity of GSK3377794 observed in earlier trials, this larger clinical trial is being initiated to establish and further discern the efficacy and safety of GSK3377794 in this biomarker-selected metastatic SS patient population. This innovative Master Protocol study design permits evaluation of GSK3377794 treatment in other NY-ESO-1+ tumor types in HLA A*02+ patients within separate sub-studies.
- GSK3377794 / GSK
Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_720;
P1
Peak persistence of GSK3377794 was higher in Cohort 2, likely due to higher lymphodepletion, but this did not correlate with response, unlike data previously reported in other cohorts. Further development in SS will be based on previously reported data from Cohort 1.
- cyclophosphamide intravenous / Generic Mfg.
Case studies of sarcoma and MRCLS following treatment with NY-ESO-1 TCR T Cells (GSK3377794): correlates of predictable response characteristics (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_586;
P1, P2
Upon GSK3377794 infusion, increased expression of activated immune cell cytokines was observed in serum from selected patients. Further analysis can provide insights into clinical response characteristics and identification of predictive biomarkers.
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date, Combination therapy: IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov) - Sep 25, 2019
P2, N=65, Not yet recruiting, Sponsor: GlaxoSmithKline
Further analysis can provide insights into clinical response characteristics and identification of predictive biomarkers. Trial primary completion date: Dec 2025 --> Jul 2021
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date, Combination therapy: IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov) - Sep 22, 2019
P2, N=65, Not yet recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2025 --> Jul 2021 Trial primary completion date: Jan 2022 --> Dec 2025
- GSK3377794 / GSK
NY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2766;
Epigenetic modifiers can improve GSK3377794 anti-tumour effect in lung cancer. Legal entity responsible for the study: GlaxoSmithKline.
- Keytruda (pembrolizumab) / Merck (MSD)
Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1726;
P1b/2a
Legal entity responsible for the study: GSK in collaboration with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding: GlaxoSmithKline.
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment closed, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 14, 2019
P1, N=10, Active, not recruiting, Sponsor: GlaxoSmithKline
Funding: GlaxoSmithKline. Recruiting --> Active, not recruiting
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial completion: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Jun 27, 2019
P1/2, N=9, Completed, Sponsor: Adaptimmune
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment change, Trial completion date, Trial primary completion date, Metastases: ADP-0011-007: Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma (clinicaltrials.gov) - Jun 20, 2019
P2, N=20, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=10 --> 20 | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- || letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment closed, Enrollment change, Trial primary completion date: ADP 04511: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1? (clinicaltrials.gov) - Jun 14, 2019
P1, N=45, Active, not recruiting, Sponsor: GlaxoSmithKline
N=10 --> 20 | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Recruiting --> Active, not recruiting | N=10 --> 45 | Trial primary completion date: May 2020 --> Dec 2019
- |||| letetresgene autoleucel (GSK3377794) / Adaptimmune
New P2 trial, Combination therapy: IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov) - May 29, 2019
P2, N=65, Not yet recruiting, Sponsor: GlaxoSmithKline